Literature DB >> 30192400

Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab.

Kayo Jin1, Yasushi Matsuzaki1, Eijiro Akasaka1, Hajime Nakano1, Daisuke Sawamura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30192400     DOI： 10.1111/1346-8138.14611

Source DB:  PubMed          Journal:  J Dermatol        ISSN： 0385-2407            Impact factor:   4.005


× No keyword cloud information.
  4 in total

Review 1.  Surgical Treatment of Pyoderma Gangrenosum with Negative Pressure Wound Therapy and Skin Grafting, Including Xenografts: Personal Experience and Comprehensive Review on 161 Cases.

Authors:  Klaus Eisendle; Tobias Thuile; Jenny Deluca; Maria Pichler
Journal:  Adv Wound Care (New Rochelle)       Date:  2020-04-28       Impact factor: 4.730

2.  Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab.

Authors:  Amy J Petty; Melodi J Whitley; Alexandra Balaban; Kenneth Ellington; Anne L Marano
Journal:  JAAD Case Rep       Date:  2020-06-16

Review 3.  Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments.

Authors:  Carlo Alberto Maronese; Matthew A Pimentel; May M Li; Alex G Ortega-Loayza; Angelo Valerio Marzano; Giovanni Genovese
Journal:  Am J Clin Dermatol       Date:  2022-05-24       Impact factor: 6.233

4.  Pyoderma gangrenosum treated with secukinumab: A case report.

Authors:  Meghan L McPhie; Mark G Kirchhof
Journal:  SAGE Open Med Case Rep       Date:  2020-07-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.